Developer docs
API playgroundTry for free, no card

Search company profiles

Nordic Bioscience

Full company profile

uuid00022ci

Namestring
Nordic Bioscience
Legal namestring
Nordic Bioscience A/S
Company typeenum
Private
Founded yearint
1989
Descriptiontext

Nordic Bioscience is a Danish biomarker company founded in 1989 and headquartered in Herlev, Denmark, specializing in preclinical and clinical drug development support through proprietary extracellular matrix (ECM) biomarkers. The company operates the Nordic ProteinFingerPrint Technology platform, which uses neo-epitope-specific monoclonal antibodies to quantify small collagen fragments released during tissue remodeling, enabling non-invasive assessment of fibrosis, inflammation, and fibro-inflammatory signaling across cardiovascular, hepatic, renal, gastrointestinal, rheumatic, oncology, respiratory, neuroscience, and metabolic diseases. Its portfolio spans 150+ biomarkers (60+ proprietary Nordic assays) including flagship products nordicPRO-C3, nordicPRO-C6/Endotrophin, CPa9-HNE, and RheumaTrace, validated through 700+ peer-reviewed publications and used for patient stratification, pharmacodynamic monitoring, and treatment response assessment in clinical trials.

The company serves over 100 major pharmaceutical and biotechnology companies (including Eli Lilly, Bristol Myers Squibb, Roche Diagnostics, Madrigal Pharmaceuticals, and Pliant Therapeutics) plus academic research institutions through three integrated business segments. R&D Services delivers biomarker analysis from the company's CAP/CLIA-certified central laboratory in Herlev, generating DKK 527M in FY2024 revenue with 39% YoY growth. Clinical Diagnostics is monetized through an OEM/embedded licensing model via Roche Diagnostics' cobas e platform (PRO-C3 launched commercially in May 2025 following FDA approval) and a Kit in a Box manual ELISA product line for research use only. Drug Development is operated through wholly-owned subsidiary KeyBioscience, which holds an extended strategic collaboration with Eli Lilly for DACRA molecules in obesity and metabolic diseases. The company is privately held under KKR private equity ownership (invested March 2021) with Morten Karsdal as CEO.

Short descriptiontext

Nordic Bioscience is a Danish biomarker company that develops proprietary extracellular matrix (ECM) neo-epitope assays and laboratory services for pharmaceutical, biotechnology, and academic clients worldwide to support drug development, clinical trial enrichment, and chronic disease diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHerlev, Denmark
HQ citystring
Herlev
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker development services, extracellular matrix research, fibrosis biomarker assays, preclinical drug development, clinical trial laboratory services
Industry6 codes
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code4 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biomarker Assay Development & Clinical Laboratory Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1R&D Services
TypeProfessional Services
Description

Laboratory services for biotech and pharmaceutical industries including biomarker analysis, preclinical and clinical sample analysis, and drug development support. Revenue increased 39% year-over-year, serving over 100 major pharmaceutical and biotechnology companies

nordicbioscience.com
2Clinical Diagnostics
TypeLicensing Royalties
Description

Partnership with Roche leveraging validated ECM biomarkers for diagnostic purposes. Biomarkers measured on Roche Cobas platform for IVD-based decision making

nordicbioscience.com
3Drug Development
TypeLicensing Royalties
Description

Development of DACRA molecules with Eli Lilly as potential new class of treatment for obesity and other indications. KeyBioscience subsidiary manages this collaboration

nordicbioscience.com
4Biomarker Kits and Products
TypeOne Time License
Description

Kit in a Box products - convenient lab-ready biomarker products for research use only. Includes Nordic assays portfolio of 60+ biomarkers sold directly to research institutions and pharma companies

nordicbioscience.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nordic Bioscience develops and commercializes proprietary neo-epitope biomarker assays targeting extracellular matrix (ECM) protein fragments for pharmaceutical and biotechnology drug development. Its core offerings are delivered through two channels: (1) CAP/CLIA-accredited central laboratory biomarker analysis services and (2) Kit in a Box manual ELISA products for Research Use Only. The company also licenses biomarkers to Roche Diagnostics for global IVD distribution on the Cobas platform and develops DACRA drug candidates through its KeyBioscience subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 12.4% and 9.2% increase in cardiovascular or all-cause mortality risk per 1 ng/ml rise in PRO-C6
+2 more records
Product overview1 text field

Nordic Bioscience is a Danish biomarker company offering a unified product ecosystem centered on its proprietary Nordic ProteinFingerPrint Technology platform. The core offering consists of biomarker assays (nordicPRO-C3, nordicPRO-C6, RheumaTrace, CPa9-HNE, Endotrophin) and the FIB-NIT Panel for fibrosis assessment, available via two delivery models: CAP/CLIA-accredited Laboratory Services or Kit in a Box (manual ELISA kits for RUO). The portfolio spans 77+ Nordic proprietary assays and 100+ commercial assays across 10 therapeutic areas. The company operates three integrated business segments: R&D Services for pharmaceutical companies, Clinical Diagnostics (leveraging Roche partnership for cobas e platform deployment), and Drug Development (DACRA molecules with Eli Lilly). Key differentiators include 30+ years of ECM research expertise, FDA Letters of Support for multiple biomarkers, and CAP accreditation in Scandinavia.

Product and service10 records
1Laboratory Services
CategoryClinical Laboratory Services
Description

CAP/CLIA-accredited central laboratory services offering biomarker analysis, preclinical and clinical sample analysis, and drug development support for biotech and pharmaceutical industries. Services include central lab, specialty lab, and regulatory services with 24-hour turnaround on samples analyzed from clients globally.

2NordicPRO-C3 (PRO-C3)
CategoryBiomarker Assay
Description

Neo-epitope biomarker assay quantifying a fragment of type III collagen released during extracellular matrix remodeling, enabling non-invasive measurement of active fibrogenesis and dynamic assessment of fibrosis progression and treatment response. Available via laboratory services or Kit in a Box manual ELISA for Research Use Only.

3NordicPRO-C6 (PRO-C6)
CategoryBiomarker Assay
Description

Biomarker assay measuring a fragment of type VI collagen (Endotrophin signaling molecule), enabling non-invasive quantification of fibrogenesis, tissue remodeling, and wound healing across chronic diseases. FDA-supported for HFpEF trial enrichment. Runs on the Roche Cobas e automated platform.

4RheumaTrace
CategoryBiomarker Assay
Description

Blood-based biomarker assay quantifying type I collagen turnover, serving as a pharmacodynamic marker for rheumatoid arthritis treatment monitoring and joint tissue remodeling assessment.

5CPa9-HNE (NordicCPa9-HNE)
CategoryBiomarker Assay
Description

Biomarker assay measuring a fragment of S100A9 (calprotectin) released by neutrophil elastase in blood, enabling precise assessment of active neutrophil-driven inflammation in systemic and tissue-specific conditions. FDA Letter of Support received for IBD applications.

6FIB-NIT Biomarker Panel
CategoryBiomarker Panel
Description

Fibrosis Non-Invasive Tests biomarker panel combining multiple extracellular matrix turnover markers for comprehensive non-invasive assessment of fibrotic diseases across organ systems.

7Kit in a Box
CategoryProduct Kit
Description

Convenient, lab-ready manual ELISA kit products (including PRO-C3) for Research Use Only in non-clinical settings, enabling customers to run biomarker assays in their own laboratories.

8Endotrophin (nordicEndotrophin)
CategoryBiomarker Assay
Description

Biomarker assay quantifying the intact 77-amino-acid Endotrophin signaling hormone (bioactive fragment of type VI collagen), enabling non-invasive quantification of fibro-inflammatory signaling and risk stratification in chronic disease and oncology.

9NordicIBDTrace
CategoryBiomarker Panel
Description

Biomarker panel specifically designed for inflammatory bowel disease, measuring extracellular matrix turnover markers relevant to intestinal inflammation and fibrosis assessment.

10Translational Models
CategoryResearch Service
Description

Pre-clinical research services including in vitro 3D hydrogel cell cultures (via Ectica Technologies partnership) for fibrosis drug discovery, providing a translational in vitro platform for compound screening.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-06
Description

PRO-C3 biomarker officially launched by Roche Diagnostics on Cobas platform, making it available globally for research and diagnostic use in fibrosis and chronic diseases.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-10-10
Description

KeyBioscience, a fully owned subsidiary and affiliate of Nordic Bioscience, announced extension of strategic collaboration with Eli Lilly for development of DACRA molecules for obesity and metabolic diseases treatment.

3GRIPonMASH Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-12
Description

Nordic Bioscience joined consortium of 27 European institutions to develop GRIPonMASH Diagnostic Platform for early detection of MASH, better patient stratification, and personalized lifestyle advice. Four-year project supported by IHI JU.

nordicbioscience.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-05
Description

License agreement between Nordic Bioscience and Roche enables PRO-C3 availability as Research Use Only product in China via LabCorp Shanghai, providing broader market access for Chinese drug developers.

5University Medicine Rostock
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

Nordic Bioscience joined the CombiDiag consortium, a Marie Skłodowska-Curie doctoral network funded by European Commission, focused on early detection of Alzheimer's disease using AI and data-supported diagnostic protocols including blood-based biomarkers.

nordicbioscience.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-12
Description

Strategic alliance combining Nordic Bioscience's ECM biomarker expertise with Ectica's 3D hydrogel cell culture technology for translational in vitro drug discovery models in fibrosis. Ectica licenses its cell culture platform enabling Nordic to conduct pre-clinical drug discovery services.

7Bristol Myers Squibb
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-09-14
Description

Collaboration with Bristol Myers Squibb and University of Pennsylvania resulted in PRO-C6/Endotrophin publication in NEJM Evidence for HFpEF trial enrichment. FDA Letter of Support obtained for using PRO-C6 in clinical trial patient selection.

nordicbioscience.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-06-16
Description

Strengthened collaboration for development of biomarkers for chronic diseases. PRO-C3 and PRO-C6 biomarkers transferred to Roche Cobas platform for global distribution. License agreement enables biomarker availability in China via LabCorp.

Strategic tierCoreTypeOthers
Description

Fully owned subsidiary managing DACRA drug development collaboration with Eli Lilly for obesity and other metabolic indications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established molecular diagnostics company commercializing proprietary biomarker tests (e.g., myChoice HRD, Vectra DA for RA disease activity). Comparable as a clinical-grade biomarker company serving pharma R&D and clinical decision-making, though with a much broader gene-expression and germline focus rather than ECM neo-epitopes.

TypeDirect peer
Description

Provides multiplexed biomarker testing services for clinical trials and pharmaceutical R&D. Directly comparable to Nordic Bioscience's lab services arm, with overlapping customer base (large pharma sponsors) and similar focus on protein-based biomarker panels for drug development.

TypeBroad incumbent
Description

Global contract laboratory network offering biomarker, genomic, and bioanalytical services to pharma. Overlaps with Nordic on biomarker assay services and central lab work, though Eurofins is a far broader CRO-style operation across multiple industries.

TypeDirect peer
Description

Protein biomarker discovery and diagnostics platform using aptamer-based proteomics (SomaScan). Direct competitor in protein-based biomarker services for pharma R&D and clinical applications, with comparable customer base among large pharma sponsors.

TypeDirect peer
Description

Provides proximity extension assay (PEA) technology for high-multiplex protein biomarker discovery and analysis. Directly comparable to Nordic ProteinFingerPrint on the protein biomarker platform dimension, serving pharma biomarker R&D with overlapping use cases including inflammation, oncology, and cardiometabolic disease.

TypeEmerging player
Description

Protein-based diagnostics company focused on lung disease and oncology with blood-based tests. Comparable as a small/mid-cap biomarker commercializer with pharma R&D services, though smaller scale and narrower therapeutic focus than Nordic Bioscience.

TypeDirect peer
Description

Early-phase clinical and bioanalytical CRO providing biomarker and PK/PD services to pharma. Comparable service offering and customer base to Nordic's biomarker lab services, particularly for translational and pharmacodynamic biomarker work.

TypeBroad incumbent
Description

Large clinical diagnostics and central lab services company with extensive pharma R&D central lab operations. Comparable as a global biomarker lab services provider and channel partner (LabCorp Shanghai already distributes Nordic's PRO-C3 RUO in China).

TypeBroad incumbent
Description

Global CRO with deep central lab, bioanalytical, and biomarker services for clinical trials. Overlaps with Nordic on bioanalytical biomarker testing and central lab services, though at much larger scale across many therapeutic areas.

TypeDirect peer
Description

Manufacturer of multiplex immunoassay platforms (Meso Scale Discovery / MSD) widely used for protein biomarker validation in pharma R&D. Comparable as a protein biomarker technology provider serving pharma, though focused on instrument/platform sales rather than a proprietary neo-epitope biomarker franchise like Nordic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nordic Bioscience

Biomarker Assay Development & Clinical Laboratory Servicesnordicbioscience.com

Nordic Bioscience is a Danish biomarker company that develops proprietary extracellular matrix (ECM) neo-epitope assays and laboratory services for pharmaceutical, biotechnology, and academic clients worldwide to support drug development, clinical trial enrichment, and chronic disease diagnostics.

What Nordic Bioscience does

Nordic Bioscience is a Danish biomarker company founded in 1989 and headquartered in Herlev, Denmark, specializing in preclinical and clinical drug development support through proprietary extracellular matrix (ECM) biomarkers. The company operates the Nordic ProteinFingerPrint Technology platform, which uses neo-epitope-specific monoclonal antibodies to quantify small collagen fragments released during tissue remodeling, enabling non-invasive assessment of fibrosis, inflammation, and fibro-inflammatory signaling across cardiovascular, hepatic, renal, gastrointestinal, rheumatic, oncology, respiratory, neuroscience, and metabolic diseases. Its portfolio spans 150+ biomarkers (60+ proprietary Nordic assays) including flagship products nordicPRO-C3, nordicPRO-C6/Endotrophin, CPa9-HNE, and RheumaTrace, validated through 700+ peer-reviewed publications and used for patient stratification, pharmacodynamic monitoring, and treatment response assessment in clinical trials.

The company serves over 100 major pharmaceutical and biotechnology companies (including Eli Lilly, Bristol Myers Squibb, Roche Diagnostics, Madrigal Pharmaceuticals, and Pliant Therapeutics) plus academic research institutions through three integrated business segments. R&D Services delivers biomarker analysis from the company's CAP/CLIA-certified central laboratory in Herlev, generating DKK 527M in FY2024 revenue with 39% YoY growth. Clinical Diagnostics is monetized through an OEM/embedded licensing model via Roche Diagnostics' cobas e platform (PRO-C3 launched commercially in May 2025 following FDA approval) and a Kit in a Box manual ELISA product line for research use only. Drug Development is operated through wholly-owned subsidiary KeyBioscience, which holds an extended strategic collaboration with Eli Lilly for DACRA molecules in obesity and metabolic diseases. The company is privately held under KKR private equity ownership (invested March 2021) with Morten Karsdal as CEO.

Nordic Bioscience firmographics

Firmographics
Name
Nordic Bioscience
Legal name
Nordic Bioscience A/S
Website
https://nordicbioscience.com
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
101–250 employees
Short description
Nordic Bioscience is a Danish biomarker company that develops proprietary extracellular matrix (ECM) neo-epitope assays and laboratory services for pharmaceutical, biotechnology, and academic clients worldwide to support drug development, clinical trial enrichment, and chronic disease diagnostics.
Ownership category
akta.pro rank

Nordic Bioscience industry classification

Industry
Product category
Biomarker Assay Development & Clinical Laboratory Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biomarker development services
  • Extracellular matrix research
  • Fibrosis biomarker assays
  • Preclinical drug development
  • Clinical trial laboratory services

Where Nordic Bioscience is headquartered

Location

Headquarters

HQ city
Herlev
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Nordic Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. R&D Services: Laboratory services for biotech and pharmaceutical industries including biomarker analysis, preclinical and clinical sample analysis, and drug development support. Revenue increased 39% year-over-year, serving over 100 major pharmaceutical and biotechnology companies
  2. Clinical Diagnostics: Partnership with Roche leveraging validated ECM biomarkers for diagnostic purposes. Biomarkers measured on Roche Cobas platform for IVD-based decision making
  3. Drug Development: Development of DACRA molecules with Eli Lilly as potential new class of treatment for obesity and other indications. KeyBioscience subsidiary manages this collaboration
  4. Biomarker Kits and Products: Kit in a Box products - convenient lab-ready biomarker products for research use only. Includes Nordic assays portfolio of 60+ biomarkers sold directly to research institutions and pharma companies

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Nordic Bioscience product offering

Product offering

Core offering

Nordic Bioscience develops and commercializes proprietary neo-epitope biomarker assays targeting extracellular matrix (ECM) protein fragments for pharmaceutical and biotechnology drug development. Its core offerings are delivered through two channels: (1) CAP/CLIA-accredited central laboratory biomarker analysis services and (2) Kit in a Box manual ELISA products for Research Use Only. The company also licenses biomarkers to Roche Diagnostics for global IVD distribution on the Cobas platform and develops DACRA drug candidates through its KeyBioscience subsidiary.

Product overview

Nordic Bioscience is a Danish biomarker company offering a unified product ecosystem centered on its proprietary Nordic ProteinFingerPrint Technology platform. The core offering consists of biomarker assays (nordicPRO-C3, nordicPRO-C6, RheumaTrace, CPa9-HNE, Endotrophin) and the FIB-NIT Panel for fibrosis assessment, available via two delivery models: CAP/CLIA-accredited Laboratory Services or Kit in a Box (manual ELISA kits for RUO). The portfolio spans 77+ Nordic proprietary assays and 100+ commercial assays across 10 therapeutic areas. The company operates three integrated business segments: R&D Services for pharmaceutical companies, Clinical Diagnostics (leveraging Roche partnership for cobas e platform deployment), and Drug Development (DACRA molecules with Eli Lilly). Key differentiators include 30+ years of ECM research expertise, FDA Letters of Support for multiple biomarkers, and CAP accreditation in Scandinavia.

Differentiator

Problem solved

Functional benefit

Products and services

  • Laboratory Services CAP/CLIA-accredited central laboratory services offering biomarker analysis, preclinical and clinical sample analysis, and drug development support for biotech and pharmaceutical industries. Services include central lab, specialty lab, and regulatory services with 24-hour turnaround on samples analyzed from clients globally.
  • NordicPRO-C3 (PRO-C3) Neo-epitope biomarker assay quantifying a fragment of type III collagen released during extracellular matrix remodeling, enabling non-invasive measurement of active fibrogenesis and dynamic assessment of fibrosis progression and treatment response. Available via laboratory services or Kit in a Box manual ELISA for Research Use Only.
  • NordicPRO-C6 (PRO-C6) Biomarker assay measuring a fragment of type VI collagen (Endotrophin signaling molecule), enabling non-invasive quantification of fibrogenesis, tissue remodeling, and wound healing across chronic diseases. FDA-supported for HFpEF trial enrichment. Runs on the Roche Cobas e automated platform.
  • RheumaTrace Blood-based biomarker assay quantifying type I collagen turnover, serving as a pharmacodynamic marker for rheumatoid arthritis treatment monitoring and joint tissue remodeling assessment.
  • CPa9-HNE (NordicCPa9-HNE) Biomarker assay measuring a fragment of S100A9 (calprotectin) released by neutrophil elastase in blood, enabling precise assessment of active neutrophil-driven inflammation in systemic and tissue-specific conditions. FDA Letter of Support received for IBD applications.
  • FIB-NIT Biomarker Panel Fibrosis Non-Invasive Tests biomarker panel combining multiple extracellular matrix turnover markers for comprehensive non-invasive assessment of fibrotic diseases across organ systems.
  • Kit in a Box Convenient, lab-ready manual ELISA kit products (including PRO-C3) for Research Use Only in non-clinical settings, enabling customers to run biomarker assays in their own laboratories.
  • Endotrophin (nordicEndotrophin) Biomarker assay quantifying the intact 77-amino-acid Endotrophin signaling hormone (bioactive fragment of type VI collagen), enabling non-invasive quantification of fibro-inflammatory signaling and risk stratification in chronic disease and oncology.
  • NordicIBDTrace Biomarker panel specifically designed for inflammatory bowel disease, measuring extracellular matrix turnover markers relevant to intestinal inflammation and fibrosis assessment.
  • Translational Models Pre-clinical research services including in vitro 3D hydrogel cell cultures (via Ectica Technologies partnership) for fibrosis drug discovery, providing a translational in vitro platform for compound screening.

Quantifiable outcome

  • 12.4% and 9.2% increase in cardiovascular or all-cause mortality risk per 1 ng/ml rise in PRO-C6
  • +2 more outcomes

Companies that use Nordic Bioscience

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Nordic Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature7 records

Nordic Bioscience partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship, core and regional.

  • Roche DiagnosticsflagshipOEM/ Whitelabel/ Licensing Partner · 6 May 2025PRO-C3 biomarker officially launched by Roche Diagnostics on Cobas platform, making it available globally for research and diagnostic use in fibrosis and chronic diseases.
  • Eli LillyflagshipStrategic or Co-development Partner · 10 October 2024KeyBioscience, a fully owned subsidiary and affiliate of Nordic Bioscience, announced extension of strategic collaboration with Eli Lilly for development of DACRA molecules for obesity and metabolic diseases treatment.
  • GRIPonMASH ConsortiumcoreStrategic or Co-development Partner · 12 February 2024Nordic Bioscience joined consortium of 27 European institutions to develop GRIPonMASH Diagnostic Platform for early detection of MASH, better patient stratification, and personalized lifestyle advice. Four-year project supported by IHI JU.
  • LabCorp (China)regionalChannel Partner/ Reseller/ Distributor · 5 February 2024License agreement between Nordic Bioscience and Roche enables PRO-C3 availability as Research Use Only product in China via LabCorp Shanghai, providing broader market access for Chinese drug developers.
  • University Medicine RostockcoreStrategic or Co-development Partner · 1 February 2024Nordic Bioscience joined the CombiDiag consortium, a Marie Skłodowska-Curie doctoral network funded by European Commission, focused on early detection of Alzheimer's disease using AI and data-supported diagnostic protocols including blood-based biomarkers.
  • Ectica TechnologiescoreStrategic or Co-development Partner · 12 December 2023Strategic alliance combining Nordic Bioscience's ECM biomarker expertise with Ectica's 3D hydrogel cell culture technology for translational in vitro drug discovery models in fibrosis. Ectica licenses its cell culture platform enabling Nordic to conduct pre-clinical drug discovery services.
  • Bristol Myers SquibbflagshipStrategic or Co-development Partner · 14 September 2022Collaboration with Bristol Myers Squibb and University of Pennsylvania resulted in PRO-C6/Endotrophin publication in NEJM Evidence for HFpEF trial enrichment. FDA Letter of Support obtained for using PRO-C6 in clinical trial patient selection.
  • Roche DiagnosticsflagshipStrategic or Co-development Partner · 16 June 2022Strengthened collaboration for development of biomarkers for chronic diseases. PRO-C3 and PRO-C6 biomarkers transferred to Roche Cobas platform for global distribution. License agreement enables biomarker availability in China via LabCorp.
  • KeyBioscience (Subsidiary)coreOthersFully owned subsidiary managing DACRA drug development collaboration with Eli Lilly for obesity and other metabolic indications.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Nordic Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Myriad Genetics: Established molecular diagnostics company commercializing proprietary biomarker tests (e.g., myChoice HRD, Vectra DA for RA disease activity). Comparable as a clinical-grade biomarker company serving pharma R&D and clinical decision-making, though with a much broader gene-expression and germline focus rather than ECM neo-epitopes.
  • Eurofins Scientific: Global contract laboratory network offering biomarker, genomic, and bioanalytical services to pharma. Overlaps with Nordic on biomarker assay services and central lab work, though Eurofins is a far broader CRO-style operation across multiple industries.
  • LabCorp (Laboratory Corporation of America): Large clinical diagnostics and central lab services company with extensive pharma R&D central lab operations. Comparable as a global biomarker lab services provider and channel partner (LabCorp Shanghai already distributes Nordic's PRO-C3 RUO in China).
  • Covance (Labcorp Drug Development): Global CRO with deep central lab, bioanalytical, and biomarker services for clinical trials. Overlaps with Nordic on bioanalytical biomarker testing and central lab services, though at much larger scale across many therapeutic areas.

Direct peers

  • Rules-Based Medicine (a Q² Solutions company): Provides multiplexed biomarker testing services for clinical trials and pharmaceutical R&D. Directly comparable to Nordic Bioscience's lab services arm, with overlapping customer base (large pharma sponsors) and similar focus on protein-based biomarker panels for drug development.
  • SomaLogic: Protein biomarker discovery and diagnostics platform using aptamer-based proteomics (SomaScan). Direct competitor in protein-based biomarker services for pharma R&D and clinical applications, with comparable customer base among large pharma sponsors.
  • Olink Holding: Provides proximity extension assay (PEA) technology for high-multiplex protein biomarker discovery and analysis. Directly comparable to Nordic ProteinFingerPrint on the protein biomarker platform dimension, serving pharma biomarker R&D with overlapping use cases including inflammation, oncology, and cardiometabolic disease.
  • Celerion: Early-phase clinical and bioanalytical CRO providing biomarker and PK/PD services to pharma. Comparable service offering and customer base to Nordic's biomarker lab services, particularly for translational and pharmacodynamic biomarker work.
  • Meso Scale Diagnostics: Manufacturer of multiplex immunoassay platforms (Meso Scale Discovery / MSD) widely used for protein biomarker validation in pharma R&D. Comparable as a protein biomarker technology provider serving pharma, though focused on instrument/platform sales rather than a proprietary neo-epitope biomarker franchise like Nordic.

Emerging players

  • Biodesix: Protein-based diagnostics company focused on lung disease and oncology with blood-based tests. Comparable as a small/mid-cap biomarker commercializer with pharma R&D services, though smaller scale and narrower therapeutic focus than Nordic Bioscience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nordic Bioscience social profiles

Digital presence

Nordic Bioscience compliance and trust

Trust signal

Compliance3 records

Nordic Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nordic Bioscience leadership team

Management profile

Number of profiles

Profiles3 records

Nordic Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nordic Bioscience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nordic Bioscience M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nordic Bioscience

What does Nordic Bioscience do?

Nordic Bioscience develops and commercializes proprietary neo-epitope biomarker assays targeting extracellular matrix (ECM) protein fragments for pharmaceutical and biotechnology drug development. Its core offerings are delivered through two channels: (1) CAP/CLIA-accredited central laboratory biomarker analysis services and (2) Kit in a Box manual ELISA products for Research Use Only. The company also licenses biomarkers to Roche Diagnostics for global IVD distribution on the Cobas platform and develops DACRA drug candidates through its KeyBioscience subsidiary.

Is Nordic Bioscience a public or private company?

Nordic Bioscience is a private company. It is classified as private equity controlled and is currently operating.

When was Nordic Bioscience founded?

Nordic Bioscience was founded in 1989. It employs 101 to 250 people.

Where is Nordic Bioscience based?

Nordic Bioscience is headquartered in Herlev, Denmark, in the Europe region.

How does Nordic Bioscience make money?

Four revenue lines are on record. R&D Services are the primary driver. The others are clinical Diagnostics, drug Development and biomarker Kits and Products.

Who are Nordic Bioscience's main competitors?

Broad incumbents on record are Myriad Genetics, Eurofins Scientific, LabCorp (Laboratory Corporation of America) and Covance (Labcorp Drug Development). Direct peers are Rules-Based Medicine (a Q² Solutions company), SomaLogic, Olink Holding, Celerion and Meso Scale Diagnostics. Biodesix is listed as an emerging player.

Does Nordic Bioscience have an API?

No public API is recorded for Nordic Bioscience.

What industry is Nordic Bioscience in?

Nordic Bioscience's product category is Biomarker Assay Development & Clinical Laboratory Services. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRoche Diagnostics stellt Prototyp eines Endotrophin-Forschungstests bei Nordic Bioscience zur Verfügung.Roche Diagnostics is making its Endotrophin (ETP) research prototype test available on Nordic Bioscience's cobas e801 analyzers in the CLIA lab. The sandwich immunoassay quantifies intact Endotrophin, a biomarker linked to fibrosis and cardiovascular, renal, and metabolic disease, and has been measured in over 50,000 patients with cardiorenal-metabolic syndrome.LelezardRoche Diagnostics met à disposition son prototype de test de recherche sur l'endotrophine chez Nordic BioscienceRoche Diagnostics made its endotrophin test prototype available on Nordic Bioscience's cobas e 801 analyzers at the CLIA lab. The immunoassay quantifies intact endotrophin, a biomarker linked to fibrosis and cardiovascular risk, and has been measured in over 50,000 patients. The FDA has supported further research on endotrophin for clinical trial enrichment.PR NewswireRoche Diagnostics met à disposition son prototype de test de recherche sur l'endotrophine chez Nordic BioscienceRoche Diagnostics is making its Endotrophin (ETP) research prototype assay available on its cobas e 801 analyzer at Nordic Bioscience's CLIA laboratory. The immunoassay quantifies intact endotrophin, a biomarker linked to fibrosis and cardiovascular risk, and has been measured in over 50,000 patients. The FDA has issued a letter supporting further research on endotrophin for clinical trial enrichment.PR NewswireRoche Diagnostics pone a disposición de Nordic Bioscience un ensayo prototipo para investigar la endotrofinaRoche Diagnostics is making its Endotrophin (ETP) research prototype assay available on cobas e801 analyzers at Nordic Bioscience's CLIA laboratory. The sandwich immunoassay quantifies intact endotrophin, a 77-amino-acid peptide linked to fibrosis and cardiovascular, renal, and metabolic disease. The assay has been used in over 50,000 patients, and the FDA has issued a letter of support for further research in heart failure with preserved ejection fraction.PR Newswire APACRoche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic BioscienceRoche Diagnostics is making its Endotrophin research prototype assay available on the cobas e801 analyzer at Nordic Bioscience's CLIA lab. The sandwich immunoassay quantifies Endotrophin, a fibrosis and inflammation biomarker, and has been measured in over 50,000 patients with cardio-kidney-metabolic disease.PR NewswireRoche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic BioscienceRoche Diagnostics is making its Endotrophin research prototype assay available on the cobas e801 analyzer at Nordic Bioscience's CLIA lab. The sandwich immunoassay quantifies the 77-amino-acid Endotrophin hormone, associated with fibrosis and adverse outcomes in cardio-kidney-metabolic disease. The assay has been measured in over 50,000 patients, and the FDA has issued a letter of support for its research as a trial enrichment tool in heart failure with preserved ejection fraction.AktienRoche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic BioscienceRoche Diagnostics is making its Endotrophin research prototype assay available on Nordic Bioscience's cobas e801 analyzers. The sandwich immunoassay quantifies Endotrophin, a fibrosis and inflammation biomarker, and has been measured in over 50,000 patients with cardio-kidney-metabolic disease. Elevated levels are linked to mortality and adverse outcomes in heart failure with preserved ejection fraction.NewswireRoche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic BioscienceRoche Diagnostics is making its Endotrophin research prototype assay available on cobas e801 analyzers at Nordic Bioscience's CLIA lab. The sandwich immunoassay quantifies Endotrophin, a fibrosis and inflammation biomarker, and has been measured in over 50,000 patients with cardio-kidney-metabolic disease. Elevated levels are linked to mortality in heart failure with preserved ejection fraction, and the FDA has issued a letter of support for its research.PR NewswireRoche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic BioscienceRoche Diagnostics is making its Endotrophin research prototype assay available on the cobas e801 analyzer at Nordic Bioscience's CLIA lab. The sandwich immunoassay quantifies Endotrophin, a hormone linked to fibrosis and adverse outcomes in cardio-kidney-metabolic disease, and has been measured in over 50,000 patients.InvestorsinhealthcareDenmark: KKR to sell minority stake in Nordic Bioscience to founder Claus ChristiansenKKR is selling its 10% stake in Nordic Bioscience to founder Claus Christiansen. The company has doubled revenue over five years, and Christiansen will assume the board chair role after Håkan Björklund steps down.